Business
Press Release Sep 01 2023
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 01, 2023, titled "Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg".
About this update from Zydus Lifesciences Limited
[{"type":"text","content":" Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 01, 2023, titled \"Zydus receives final approval from the USFDA for Erythromycin Tablets USP, 250 mg and 500 mg\". View Attachment","length":361,"tagName":"div"}]